Synovus Financial Corp Has $106,000 Position in Sanofi SA (SNY)

Synovus Financial Corp lowered its stake in shares of Sanofi SA (NYSE:SNY) by 37.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,371 shares of the company’s stock after selling 1,402 shares during the quarter. Synovus Financial Corp’s holdings in Sanofi were worth $106,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Squar Milner Financial Services LLC acquired a new stake in Sanofi during the second quarter worth approximately $169,000. New England Research & Management Inc. acquired a new stake in Sanofi during the third quarter worth approximately $205,000. Nisa Investment Advisors LLC acquired a new stake in Sanofi during the third quarter worth approximately $205,000. Natixis acquired a new stake in Sanofi during the second quarter worth approximately $213,000. Finally, We Are One Seven LLC acquired a new stake in Sanofi during the third quarter worth approximately $227,000. 7.53% of the stock is currently owned by institutional investors and hedge funds.

In other news, major shareholder Sanofi sold 104,552 shares of the stock in a transaction on Thursday, September 6th. The stock was sold at an average price of $406.68, for a total value of $42,519,207.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.00% of the stock is owned by corporate insiders.

Several equities research analysts have weighed in on the company. ValuEngine upgraded Sanofi from a “strong sell” rating to a “sell” rating in a research note on Friday, July 20th. Guggenheim assumed coverage on Sanofi in a research note on Monday, October 8th. They set a “neutral” rating for the company. JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a research note on Monday, October 15th. Wolfe Research assumed coverage on Sanofi in a research note on Tuesday, October 23rd. They set a “market perform” rating for the company. Finally, Argus upped their target price on Sanofi from $48.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $49.50.

NYSE SNY opened at $45.59 on Friday. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.22 and a quick ratio of 0.85. Sanofi SA has a fifty-two week low of $37.43 and a fifty-two week high of $46.25. The firm has a market cap of $113.69 billion, a price-to-earnings ratio of 14.08, a price-to-earnings-growth ratio of 2.57 and a beta of 0.70.

Sanofi (NYSE:SNY) last released its earnings results on Wednesday, October 31st. The company reported $1.07 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.09. Sanofi had a return on equity of 18.18% and a net margin of 12.20%. The firm had revenue of $9.39 billion during the quarter, compared to analysts’ expectations of $9.10 billion. During the same period in the prior year, the company earned $1.71 earnings per share. The company’s quarterly revenue was up 1.5% on a year-over-year basis. As a group, analysts predict that Sanofi SA will post 3.09 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by WKRB News and is the sole property of of WKRB News. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.wkrb13.com/2018/11/10/synovus-financial-corp-has-106000-position-in-sanofi-sa-sny.html.

Sanofi Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an oral immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Featured Article: Stop Order Uses For Individual Investors

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply